Aprotinin May Increase Mortality in Low and Intermediate Risk but Not in High Risk Cardiac Surgical Patients Compared to Tranexamic Acid and ε-Aminocaproic Acid - A Meta-Analysis of Randomised and Observational Trials of over 30.000 Patients

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Meybohm, Patrick ^a   Herrmann, Eva ^a   Nierhoff, Julia ^a   Zacharowski, Kai ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID;

ACUTE KIDNEY FAILURE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; DRUG EFFECT; ERYTHROCYTE CONCENTRATE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; SURGICAL PATIENT; SYSTEMATIC REVIEW;

6-AMINOCAPROIC ACID; APROTININ; CARDIAC SURGICAL PROCEDURES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRANEXAMIC ACID;

EID: 84874594832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058009     Document Type: Article

References (31)

1. Reeves BC, Murphy GJ, (2008) Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery. Curr Opin Cardiol 23: 607-612.
2. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, et al. (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev pp. CD001886.
3. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, et al. (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358: 2319-2331.
4. Murkin JM, Falter F, Granton J, Young B, Burt C, et al. (2010) High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 110: 350-353.
5. Royston D, Bidstrup BP, Taylor KM, Sapsford RN, (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2: 1289-1291.
6. European Medicines Agency (2012) European Medicines Agency recommends lifting suspension of aprotinin. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001447.jsp&mid=WC0b01ac058004d5c1&jsenabled=true. Available: 2012 April 8.
7. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, et al. (2010) The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 110: 21-29.
8. Bernet F, Carrel T, Marbet G, Skarvan K, Stulz P, (1999) Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients. J Card Surg 14: 92-97.
9. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, et al. (1994) Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 108: 1083-1091.
10. Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, et al. (2009) The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg 109: 15-24.
11. Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, et al. (2004) Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. Curr Med Res Opin 20: 121-126.
12. Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenpera M, (2005) The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. Acta Anaesthesiol Scand 49: 1272-1279.
13. Landymore RW, Murphy JT, Lummis H, Carter C, (1997) The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Eur J Cardiothorac Surg 11: 798-800.
14. Lindvall G, Sartipy U, Ivert T, van der Linden J, (2008) Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg 86: 13-19.
15. Misfeld M, Dubbert S, Eleftheriadis S, Siemens HJ, Wagner T, et al. (1998) Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations. Ann Thorac Surg 66: 792-799.
16. Mongan PD, Brown RS, Thwaites BK, (1998) Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg 87: 258-265.
17. Schneeweiss S, Seeger JD, Landon J, Walker AM, (2008) Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358: 771-783.
18. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, et al. (2008) The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358: 784-793.
19. Sniecinski RM, Chen EP, Makadia SS, Kikura M, Bolliger D, et al. (2010) Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 24: 959-963.
20. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, et al. (2008) Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 29: 1548-1559.
21. Downs SH, Black N, (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52: 377-384.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269.
23. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283: 2008-2012.
24. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7: 10.
25. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
26. Deanda A Jr, Spiess BD, (2012) Aprotinin revisited. J Thorac Cardiovasc Surg 144: 998-1002.
27. Ferraris VA, (2013) Facts, opinions, and conclusions: Aprotinin brings out all of these. J Thorac Cardiovasc Surg 145: 240-242.
28. Mouton R, Finch D, Davies I, Binks A, Zacharowski K, (2008) Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 371: 475-482.
29. DeSantis SM, Toole JM, Kratz JM, Uber WE, Wheat MJ, et al. (2011) Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation 124: S62-69.
30. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, et al. (2010) Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 14: R148.
31. Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, et al. (2000) Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 120: 520-527.